1
|
Pardhan A, Vu K, Gallo-Hershberg D, Forbes L, Gavura S, Kukreti V. Evolving Best Practice for Take-Home Cancer Drugs. JCO Oncol Pract 2020; 17:e526-e536. [PMID: 33079644 DOI: 10.1200/op.20.00448] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Take-home cancer drugs (THCDs) have become a standard treatment of many cancers. Robust guidelines have been developed for intravenous chemotherapy drugs, but few exist for THCDs with a focus on decentralized models. Hence, Ontario Health (Cancer Care Ontario) established the Oncology Pharmacy Task Force (OPTF) to develop consensus-based recommendations on best practices for THCDs to ensure that patients receive safe, consistent, high-quality care in the community once they leave the cancer center/practice with a prescription. METHODS The OPTF included 34 members with comprehensive representation. Guidance from leading authorities was extracted through literature review, thematically analyzed, and synthesized to develop 29 recommendations. The consensus process (> 70% agreement) included a three-step modified Delphi method followed by an extensive review process. RESULTS Sixteen recommendations were developed: training and education for providers (2), drug access (1), prescribing (4), patient and family/caregiver education (3), communication (1), dispensing (3), monitoring for patient adherence and adverse effects (1), and incident reporting (1). CONCLUSION Through a rigorous methodology, the OPTF derived a robust set of recommendations similar to the ASCO/Oncology Nursing Society and ASCO/National Community Oncology Dispensing Association guidelines, further validating and strengthening the applicability across multiple jurisdictions, including those with decentralized models. Unique aspects in a decentralized model include the need for two pharmacy professionals, with one doing cognitive verification of the script and the other dispensing the medication; moreover, they optimize interprofessional communication between community providers and the cancer center/practice health care team.
Collapse
Affiliation(s)
- Aliya Pardhan
- Ontario Health (Cancer Care Ontario), Toronto, Ontario, Canada
| | - Kathy Vu
- Ontario Health (Cancer Care Ontario), Toronto, Ontario, Canada.,Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
| | - Daniela Gallo-Hershberg
- Ontario Health (Cancer Care Ontario), Toronto, Ontario, Canada.,Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
| | - Leta Forbes
- Ontario Health (Cancer Care Ontario), Toronto, Ontario, Canada.,Lakeridge Health, Oshawa, Ontario, Canada
| | - Scott Gavura
- Ontario Health (Cancer Care Ontario), Toronto, Ontario, Canada
| | - Vishal Kukreti
- Ontario Health (Cancer Care Ontario), Toronto, Ontario, Canada.,Princess Margaret Cancer Centre, Toronto, Ontario, Canada
| |
Collapse
|
2
|
Goossen K, Hess S, Lunny C, Pieper D. Database combinations to retrieve systematic reviews in overviews of reviews: a methodological study. BMC Med Res Methodol 2020; 20:138. [PMID: 32487023 PMCID: PMC7268249 DOI: 10.1186/s12874-020-00983-3] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2019] [Accepted: 04/20/2020] [Indexed: 12/30/2022] Open
Abstract
Background When conducting an Overviews of Reviews on health-related topics, it is unclear which combination of bibliographic databases authors should use for searching for SRs. Our goal was to determine which databases included the most systematic reviews and identify an optimal database combination for searching systematic reviews. Methods A set of 86 Overviews of Reviews with 1219 included systematic reviews was extracted from a previous study. Inclusion of the systematic reviews was assessed in MEDLINE, CINAHL, Embase, Epistemonikos, PsycINFO, and TRIP. The mean inclusion rate (% of included systematic reviews) and corresponding 95% confidence interval were calculated for each database individually, as well as for combinations of MEDLINE with each other database and reference checking. Results Inclusion of systematic reviews was higher in MEDLINE than in any other single database (mean inclusion rate 89.7%; 95% confidence interval [89.0–90.3%]). Combined with reference checking, this value increased to 93.7% [93.2–94.2%]. The best combination of two databases plus reference checking consisted of MEDLINE and Epistemonikos (99.2% [99.0–99.3%]). Stratification by Health Technology Assessment reports (97.7% [96.5–98.9%]) vs. Cochrane Overviews (100.0%) vs. non-Cochrane Overviews (99.3% [99.1–99.4%]) showed that inclusion was only slightly lower for Health Technology Assessment reports. However, MEDLINE, Epistemonikos, and reference checking remained the best combination. Among the 10/1219 systematic reviews not identified by this combination, five were published as websites rather than journals, two were included in CINAHL and Embase, and one was included in the database ERIC. Conclusions MEDLINE and Epistemonikos, complemented by reference checking of included studies, is the best database combination to identify systematic reviews on health-related topics.
Collapse
Affiliation(s)
- Käthe Goossen
- Institute for Research in Operative Medicine (IFOM), Faculty of Health, School of Medicine, Witten/Herdecke University, Ostmerheimer Str. 200, 51109, Cologne, Germany.
| | - Simone Hess
- Institute for Research in Operative Medicine (IFOM), Faculty of Health, School of Medicine, Witten/Herdecke University, Ostmerheimer Str. 200, 51109, Cologne, Germany
| | - Carole Lunny
- Department of Anesthesiology, Pharmacology and Therapeutics, Faculty of Medicine, Cochrane Hypertension Review Group and the Therapeutics Initiative, University of British Columbia, 2329 West Mall, Vancouver, BC, V6T 1Z4, Canada
| | - Dawid Pieper
- Institute for Research in Operative Medicine (IFOM), Faculty of Health, School of Medicine, Witten/Herdecke University, Ostmerheimer Str. 200, 51109, Cologne, Germany
| |
Collapse
|
6
|
Neuss MN, Gilmore TR, Belderson KM, Billett AL, Conti-Kalchik T, Harvey BE, Hendricks C, LeFebvre KB, Mangu PB, McNiff K, Olsen M, Schulmeister L, Von Gehr A, Polovich M. 2016 Updated American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards, Including Standards for Pediatric Oncology. J Oncol Pract 2016; 12:1262-1271. [DOI: 10.1200/jop.2016.017905] [Citation(s) in RCA: 67] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose To update the ASCO/Oncology Nursing Society (ONS) Chemotherapy Administration Safety Standards and to highlight standards for pediatric oncology. Methods The ASCO/ONS Chemotherapy Administration Safety Standards were first published in 2009 and updated in 2011 to include inpatient settings. A subsequent 2013 revision expanded the standards to include the safe administration and management of oral chemotherapy. A joint ASCO/ONS workshop with stakeholder participation, including that of the Association of Pediatric Hematology Oncology Nurses and American Society of Pediatric Hematology/Oncology, was held on May 12, 2015, to review the 2013 standards. An extensive literature search was subsequently conducted, and public comments on the revised draft standards were solicited. Results The updated 2016 standards presented here include clarification and expansion of existing standards to include pediatric oncology and to introduce new standards: most notably, two-person verification of chemotherapy preparation processes, administration of vinca alkaloids via minibags in facilities in which intrathecal medications are administered, and labeling of medications dispensed from the health care setting to be taken by the patient at home. The standards were reordered and renumbered to align with the sequential processes of chemotherapy prescription, preparation, and administration. Several standards were separated into their respective components for clarity and to facilitate measurement of adherence to a standard. Conclusion As oncology practice has changed, so have chemotherapy administration safety standards. Advances in technology, cancer treatment, and education and training have prompted the need for periodic review and revision of the standards. Additional information is available at http://www.asco.org/chemo-standards .
Collapse
Affiliation(s)
- Michael N. Neuss
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| | - Terry R. Gilmore
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| | - Kristin M. Belderson
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| | - Amy L. Billett
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| | - Tara Conti-Kalchik
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| | - Brittany E. Harvey
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| | - Carolyn Hendricks
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| | - Kristine B. LeFebvre
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| | - Pamela B. Mangu
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| | - Kristen McNiff
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| | - MiKaela Olsen
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| | - Lisa Schulmeister
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| | - Ann Von Gehr
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| | - Martha Polovich
- Vanderbilt Ingram Cancer Center, Nashville TN; American Society of Clinical Oncology, Alexandria, VA; Children’s Hospital Colorado, Aurora, CO; Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; The Breast Center, Bethesda, MD; Oncology Nursing Society, Pittsburgh, PA; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; New Orleans, LA; The Permanente Medical Group, San Jose, CA; and Byrdine F. Lewis School of Nursing and Health Professions, Atlanta, GA
| |
Collapse
|
7
|
Simanovski V, Green E, Meertens E, Kaizer L, Ahmad N, Hertz S, Cheng R, Burns J, Krzyzanowska MK. Using Breakthrough Series Collaborative Methodology to Improve Safe Delivery of Chemotherapy in Ontario. J Oncol Pract 2014; 10:e240-6. [DOI: 10.1200/jop.2013.001254] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Participation in a collaborative enabled local interdisciplinary teams to develop processes and structures to support ongoing quality improvement, including formation of a sustainable structure for knowledge translation and exchange, but lack of a shared provincial target limited overall evaluation.
Collapse
Affiliation(s)
- Vicky Simanovski
- Cancer Care Ontario; Institute for Safe Medication Practices Canada; Princess Margaret Cancer Centre, Toronto; Credit Valley Hospital, Mississauga; and Grand River Hospital, Kitchener, Ontario, Canada
| | - Esther Green
- Cancer Care Ontario; Institute for Safe Medication Practices Canada; Princess Margaret Cancer Centre, Toronto; Credit Valley Hospital, Mississauga; and Grand River Hospital, Kitchener, Ontario, Canada
| | - Elaine Meertens
- Cancer Care Ontario; Institute for Safe Medication Practices Canada; Princess Margaret Cancer Centre, Toronto; Credit Valley Hospital, Mississauga; and Grand River Hospital, Kitchener, Ontario, Canada
| | - Leonard Kaizer
- Cancer Care Ontario; Institute for Safe Medication Practices Canada; Princess Margaret Cancer Centre, Toronto; Credit Valley Hospital, Mississauga; and Grand River Hospital, Kitchener, Ontario, Canada
| | - Noor Ahmad
- Cancer Care Ontario; Institute for Safe Medication Practices Canada; Princess Margaret Cancer Centre, Toronto; Credit Valley Hospital, Mississauga; and Grand River Hospital, Kitchener, Ontario, Canada
| | - Sherrie Hertz
- Cancer Care Ontario; Institute for Safe Medication Practices Canada; Princess Margaret Cancer Centre, Toronto; Credit Valley Hospital, Mississauga; and Grand River Hospital, Kitchener, Ontario, Canada
| | - Roger Cheng
- Cancer Care Ontario; Institute for Safe Medication Practices Canada; Princess Margaret Cancer Centre, Toronto; Credit Valley Hospital, Mississauga; and Grand River Hospital, Kitchener, Ontario, Canada
| | - Judy Burns
- Cancer Care Ontario; Institute for Safe Medication Practices Canada; Princess Margaret Cancer Centre, Toronto; Credit Valley Hospital, Mississauga; and Grand River Hospital, Kitchener, Ontario, Canada
| | - Monika K. Krzyzanowska
- Cancer Care Ontario; Institute for Safe Medication Practices Canada; Princess Margaret Cancer Centre, Toronto; Credit Valley Hospital, Mississauga; and Grand River Hospital, Kitchener, Ontario, Canada
| |
Collapse
|